2. Search Result
Search Result
Results for "

antidiabetic effect

" in MedChemExpress (MCE) Product Catalog:

34

Inhibitors & Agonists

1

Peptides

20

Natural
Products

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-N3015
    Bruceine E

    		Others Metabolic Disease
    Bruceine E is a quassinoid from seeds of Brucea javanica (L.) Merr, exhibiting hypoglycemia effect . Bruceine E exhibits blood glucose lowering effect in both nondiabetic mice and Streptozotocin (STZ (HY-13753))-induced diabetic rats at lower dose .
    Bruceine E
  • HY-N6039
    Gentianine
    1 Publications Verification

    		 Others Metabolic Disease Inflammation/Immunology
    Gentianine, an active metabolite of Swertiamarin, has anti-diabetic effect and anti-inflammatory property .
    Gentianine
  • HY-119322
    Tifenazoxide

    NN414

    		 Potassium Channel Metabolic Disease
    Tifenazoxide (NN414) is a potent, orally active and SUR1/Kir6.2 selective K ATP channels opener. Tifenazoxide has antidiabetic effect, can inhibit glucose stimulated insulin release in vitro and in vivo, and has a beneficial effect on glucose homeostasis .
    Tifenazoxide
  • HY-120401
    Glybuzole

    Desaglybuzole

    		 Others Metabolic Disease
    Glybuzole (Desaglybuzole) is an orally active hypoglycaemic agent that has antidiabetic effect .
    Glybuzole
  • HY-N8204
    Siaresinolic acid 28-O-β-D-glucopyranosyl ester

    		Others Metabolic Disease Cancer
    Siaresinolic acid 28-O-β-D-glucopyranosyl ester possesses anti-tumor and antidiabetic effect activity .
    Siaresinolic acid 28-O-β-D-glucopyranosyl ester
  • HY-108711
    GPR120 Agonist 1

    		Free Fatty Acid Receptor Metabolic Disease
    GPR120 Agonist 1 is a potent and selective GPR120 agonist, and possesses promising antidiabetic effect and good safety profile to be a development candidate .
    GPR120 Agonist 1
  • HY-P10591
    Olatorepatide

    Olatorepatidum

    		 Insulin Receptor GLP Receptor Metabolic Disease
    Olatorepatide (Olatorepatidum) is a dual gastric inhibitory polypeptide (GIP) receptor and glucagon like peptide 1 (GLP-1) receptor agonist, with antidiabetic effect .
    Olatorepatide
  • HY-N1995
    Methylswertianin

    		Others Metabolic Disease
    Methylswertianin is an active constituent in Swertia punicea Hemsl, with anti-diabetic effect. Methylswertianin can abates type-2 diabetes, likely via the improvement of insulin resistance (IR) .
    Methylswertianin
  • HY-126198A
    Linogliride fumarate

    McN-3935 fumarate

    		 Antibiotic Metabolic Disease
    Linogliride (MCN-3935) fumarate is an antidiabetic agent. Linogliride fumarate (100 μM) does not affect insulin secretion in the absence of glucose, but has a significant insulinotropic effect in the presence of 5.5 mM glucose .
    Linogliride fumarate
  • HY-126198
    Linogliride

    McN-3935

    		 Antibiotic Metabolic Disease
    Linogliride (MCN-3935) is an antidiabetic agent. Linogliride (100 μM) does not affect insulin secretion in the absence of glucose, but has a significant insulinotropic effect in the presence of 5.5 mM glucose .
    Linogliride
  • HY-N11551
    Salvifaricin

    		Others Others Metabolic Disease
    Salvifaricin is an orally active diterpenoid compound that can be isolated from Salvia leucantha Cav. and Salvia hispanica L.. Salvifaricin significantly reduces fasting blood glucose and serum triglyceride (TG) levels, and has anti-diabetic effect .
    Salvifaricin
  • HY-148418
    TUG-499

    		Free Fatty Acid Receptor Metabolic Disease
    TUG-499 is a selective free fatty acid receptor 1 (FFAR1 or GPR40) (Free Fatty Acid Receptor) agonist with a pEC50 of 7.39. TUG-499 exhibits >100-fold selectivity over the related receptors FFA2, FFA3, and the nuclear receptor PPARγ and other diverse receptors, ion channels, and transporters. TUG-499 can be used for the research of type 2 diabetes . TUG-499 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    TUG-499
  • HY-N2486
    Desoxyrhaponticin
    1 Publications Verification

    		 Fatty Acid Synthase (FASN) Apoptosis Cancer
    Desoxyrhaponticin is a kind of oral drug that inhibits effective fatty acid synthesis (FASN), and has a fatal effect on cancer cells. Desoxyrhaponticin has the ability to inhibit glucose uptake, improve oral glucose tolerance as a diabetic agent, and possess anti-diabetic effects.
    Desoxyrhaponticin
  • HY-119322R
    Tifenazoxide (Standard)

    		Potassium Channel Metabolic Disease
    Tifenazoxide (Standard) is the analytical standard of Tifenazoxide. This product is intended for research and analytical applications. Tifenazoxide (NN414) is a potent, orally active and SUR1/Kir6.2 selective KATP channels opener. Tifenazoxide has antidiabetic effect, can inhibit glucose stimulated insulin release in vitro and in vivo, and has a beneficial effect on glucose homeostasis .
    Tifenazoxide (Standard)
  • HY-N9536
    Cinnamtannin A2

    		GLP Receptor Metabolic Disease
    Cinnamtannin A2, a tetrameric procyanidin, can increases GLP-1 and insulin secretion in mice. Cinnamtannin A2 could upregulate the expression of corticotrophin releasing hormone. Cinnamtannin A2 exhibits antioxidant, anti-diabetic and nephroprotective effect .
    Cinnamtannin A2
  • HY-N1510
    Kaempferol 3-O-gentiobioside

    		Glycosidase Metabolic Disease
    Kaempferol 3-O-gentiobioside is a flavonoid isolated from C. alata leaves with antidiabetic activity. Kaempferol 3-O-gentiobioside possesses activity against α-glucosidase and displays carbohydrate enzyme inhibitory effect with an IC50 of 50.0 µM .
    Kaempferol 3-O-gentiobioside
  • HY-134769
    OPC-163493

    		Mitochondrial Metabolism Reactive Oxygen Species (ROS) Cardiovascular Disease Metabolic Disease
    OPC-163493 is an orally active and liver-targeted mitochondrial uncoupling agent. OPC-163493 reduces the production of mitochondrial Δψ and ROS. OPC-163493 has anti-diabetic and lipid-lowering effects. In addition, OPC-163493 has a protective effect on cardiovascular disease .
    OPC-163493
  • HY-162320
    PPARγ agonist 12

    		PPAR Metabolic Disease
    PPARγ agonist 12 (compound 9i) is a potent and selective PPARγ agonist with EC50s of 3.98 and 15.42 μM against PPARγ and PPARδ, respectively. PPARγ agonist 12 improves insulin secretion and has anti-diabetic effect .
    PPARγ agonist 12
  • HY-N2486R
    Desoxyrhaponticin (Standard)

    		Reference Standards Fatty Acid Synthase (FASN) Apoptosis Cancer
    Desoxyrhaponticin (Standard) is the analytical standard of Desoxyrhaponticin. This product is intended for research and analytical applications. Desoxyrhaponticin is a kind of oral drug that inhibits effective fatty acid synthesis (FASN), and has a fatal effect on cancer cells. Desoxyrhaponticin has the ability to inhibit glucose uptake, improve oral glucose tolerance as a diabetic agent, and possess anti-diabetic effects .
    Desoxyrhaponticin (Standard)
  • HY-108521
    HX531

    		RAR/RXR Apoptosis MDM-2/p53 Metabolic Disease Cancer
    HX531 is an orally active RXR antagonist with an IC50 of 18 nM. HX531 upregulates the p53-p21Cip1 pathway. HX531 abrogates the anti-apoptotic effect of t-RA. HX531 exerts anti-obesity, anti-diabetic and anti-melanoma activities .
    HX531
  • HY-N6642
    Ankaflavin

    		PPAR Apoptosis Inflammation/Immunology Cancer
    Ankaflavin, isolated from Monascus-Fermented red rice, is an orally active PPARγ agonist. Ankaflavin exhibits selective cytotoxic effect and induces cell death through apoptosis on cancer cells. Ankaflavin has anti-inflammatory, anti-cancer, antiatherosclerotic, and hypolipidemic effects .
    Ankaflavin
  • HY-N7912
    Pterosin A

    (2S)-Pterosin A

    		 AMPK PEPCK GSK-3 GLUT Akt p38 MAPK Reactive Oxygen Species (ROS) Metabolic Disease
    Pterosin A ((2S)-Pterosin A) is a sesquiterpene compound. Pterosin A is an orally active AMPK activator with anti-diabetic effect. Pterosin A can promote glucose uptake, increase serum insulin, and improve hyperglycemia and glucose intolerance. Pterosin A can prevent insulin-secreting cells death and reduce ROS production. Pterosin A can be used for the research of metabolic disease, such as diabetes .
    Pterosin A
  • HY-106181A
    Rivoglitazone hydrochloride

    R-106056 hydrochloride

    		 PPAR Metabolic Disease
    Rivoglitazone hydrochloride (R-106056 hydrochloride) is a peroxisome proliferator-activated receptor-γ (PPAR-γ) agonist. Rivoglitazone hydrochloride (R-106056 hydrochloride) exerts its anti-diabetic effect by activating PPARγ to regulate the expression of a large number of genes related to lipid and glucose metabolism. Rivoglitazone hydrochloride (R-106056 hydrochloride) can be used to study insulin secretion and insulin resistance in animal models of diabetes .
    Rivoglitazone hydrochloride
  • HY-160602
    CPL207280

    		Free Fatty Acid Receptor Metabolic Disease
    CPL207280 is an orally active GPR40/FFA1 agonist with an antidiabetic effect. CPL207280 can effectively enhance glucose-stimulated insulin secretion and improve glucose tolerance in MIN6 pancreatic β-cells as well as in healthy Wistar Han rats and diabetic rat models. CPL207280 can be used for the research of type 2 diabetes .
    CPL207280
  • HY-N1510R
    Kaempferol 3-O-gentiobioside (Standard)

    		Reference Standards Glycosidase Metabolic Disease
    Kaempferol 3-O-gentiobioside (Standard) is the analytical standard of Kaempferol 3-O-gentiobioside. This product is intended for research and analytical applications. Kaempferol 3-O-gentiobioside is a flavonoid isolated from C. alata leaves with antidiabetic activity. Kaempferol 3-O-gentiobioside possesses activity against α-glucosidase and displays carbohydrate enzyme inhibitory effect with an IC50 of 50.0 μM .
    Kaempferol 3-O-gentiobioside (Standard)
  • HY-162639
    α-Glucosidase-IN-68

    		Glycosidase Cholinesterase (ChE) Neurological Disease Metabolic Disease
    α-Glucosidase-IN-68 (Compound 2) is an inhibitor for α-Glucosidase, AChE, and BChE, with IC50 of 0.251, 0.774 and 0.793 μM, respectively. α-Glucosidase-IN-68 exhibits antioxidant efficacy, with IC50 of 0.69 μM and 0.02 μM, in DPPH and ABTS experiments. α-Glucosidase-IN-68 exhibits antidiabetic effect in Streptozotocin (HY-13753)-induced diabetic rat models .
    α-Glucosidase-IN-68
  • HY-N2447
    Amarogentin
    2 Publications Verification

    		 AMPK Apoptosis Metabolic Disease Cancer
    Amarogentin is a secoiridoid glycoside that is mainly extracted from Swertia and Gentiana roots. Amarogentin exhibits many biological effects, including anti-oxidative, anti-tumour, and anti-diabetic activities. Amarogentin exerts hepatoprotective and immunomodulatory effects. Amarogentin promotes apoptosis, arrests G2/M cell cycle and downregulates of PI3K/Akt/mTOR signalling pathways. Amarogentin exerts beneficial vasculo-metabolic effect by activating AMPK .
    Amarogentin
  • HY-N7676
    Marein
    3 Publications Verification

    		 AMPK HDAC Cardiovascular Disease Neurological Disease Metabolic Disease
    Marein has the neuroprotective effect due to a reduction of damage to mitochondria function and activation of the AMPK signal pathway. Marein improves insulin resistance induced by high glucose in HepG2 cells through CaMKK/AMPK/GLUT1 to promote glucose uptake, through IRS/Akt/GSK-3β to increase glycogen synthesis, and through Akt/FoxO1 to decrease gluconeogenesis. Marein is a HDAC inhibitor with an IC50 of 100 μM. Marein has beneficial antioxidative, antihypertensive, antihyperlipidemic and antidiabetic effects .
    Marein
  • HY-N2447R
    Amarogentin (Standard)

    		Reference Standards AMPK Apoptosis Metabolic Disease Cancer
    Amarogentin (Standard) is the analytical standard of Amarogentin. This product is intended for research and analytical applications. Amarogentin is a secoiridoid glycoside that is mainly extracted from Swertia and Gentiana roots. Amarogentin exhibits many biological effects, including anti-oxidative, anti-tumour, and anti-diabetic activities. Amarogentin exerts hepatoprotective and immunomodulatory effects. Amarogentin promotes apoptosis, arrests G2/M cell cycle and downregulates of PI3K/Akt/mTOR signalling pathways. Amarogentin exerts beneficial vasculo-metabolic effect by activating AMPK .
    Amarogentin (Standard)
  • HY-N0755
    Rhoifolin

    		Insulin Receptor GLUT NF-κB p38 MAPK Autophagy Metabolic Disease Endocrinology Cancer
    Rhoifolin is a flavone glycoside can be isolated from Rhus succedanea. Rhoifolin has anti-diabetic effect acting through enhanced adiponectin secretion, tyrosine phosphorylation of insulin receptor-β and glucose transporter 4 (GLUT 4) translocation. Rhoifolin has an anti-inflammatory action via multi-level regulation of inflammatory mediators. Rhoifolin ameliorates titanium particle-stimulated osteolysis and attenuates osteoclastogenesis via RANKL-induced NF-κB and MAPK pathways. Rhoifolin also has cytotoxic activity against different cancer cell lines .
    Rhoifolin
  • HY-N16431
    NFAT-133

    		AMPK Nuclear Factor of activated T Cells (NFAT) Interleukin Related Endogenous Metabolite Metabolic Disease Inflammation/Immunology
    NFAT-133 is an aromatic polyketide with immunosuppressive and antidiabetic activity. NFAT-133 activates the AMPK pathway, promoting glucose uptake in L6 muscle fibers, thereby resisting diabetes. NFAT-133 inhibits the transcriptional activity of activated T-cell nuclear factor (NFAT), thereby suppressing the expression of IL-2 and the proliferation of T cells, demonstrating an immunosuppressive effect. NFAT-133 does not exhibit antibacterial activity or cytotoxicity, but it can weaken the production of NO in RAW264.7 cells induced by Lipopolysaccharide (LPS) (HY-D1056) .
    NFAT-133
  • HY-N0755R
    Rhoifolin (Standard)

    		Reference Standards Insulin Receptor GLUT NF-κB p38 MAPK Autophagy Metabolic Disease Endocrinology Cancer
    Rhoifolin (Standard) is the analytical standard of Rhoifolin. This product is intended for research and analytical applications. Rhoifolin is a flavone glycoside can be isolated from Rhus succedanea. Rhoifolin has anti-diabetic effect acting through enhanced adiponectin secretion, tyrosine phosphorylation of insulin receptor-β and glucose transporter 4 (GLUT 4) translocation. Rhoifolin has an anti-inflammatory action via multi-level regulation of inflammatory mediators. Rhoifolin ameliorates titanium particle-stimulated osteolysis and attenuates osteoclastogenesis via RANKL-induced NF-κB and MAPK pathways. Rhoifolin also has cytotoxic activity against different cancer cell lines .
    Rhoifolin (Standard)
  • HY-16942
    Damulin B
    1 Publications Verification

    		 Apoptosis Reactive Oxygen Species (ROS) Bcl-2 Family CDK MMP Interleukin Related MDM-2/p53 Metabolic Disease Inflammation/Immunology Cancer
    Damulin B is a dammarane-type saponin found in Gynostemma pentaphyllum. Damulin B can inhibit cancer cell apoptosis, decrease mitochondrial membrane potential, inhibit ROS production and cause G0/G1 phase arrest. Damulin B can prevent Cisplatin (HY-17394)-induced acute kidney injury and induce hair growth. Damulin B shows anti-inflammation anti-diabetic and anti-obesity effect. Damulin B can be used for the researches of cancer, inflammation, metabolic disease, such as lung cancer, osteoarthritis and diabetes .
    Damulin B
  • HY-Y0790R
    Cuminaldehyde (Standard)

    p-Isopropylbenzaldehyde (Standard)

    		 α-synuclein Reference Standards Infection Neurological Disease Inflammation/Immunology Cancer
    Cuminaldehyde Standard is the analytical standard of Cuminaldehyde. This product is intended for research and analytical applications. Cuminaldehyde is the main component of Cuminum cyminum and has multiple biological activities, including anti-inflammatory, anti-cancer, anti-diabetic, anti-injury, anti-neuropathy and antibacterial effects. Cuminaldehyde is an inhibitor of aldose reductase (IC50= 0.00085 mg/mL) and α-glucosidase (IC50=0.5 mg/mL). Cuminaldehyde also inhibits the fibrillation of α-synuclein and prevents its aggregation Cuminaldehyde can induce apoptosis in colon adenocarcinoma cells by targeting topoisomerase I and II. In addition, Cuminaldehyde also exerts anti-inflammatory activity by inhibiting lipoxygenase. Cuminaldehyde has a strong inhibitory effect on the growth of Aspergillus flavus and the biosynthesis of aflatoxin B1 (AFB1). Cuminaldehyde can exert anti-injury and anti-neuropathy effects by participating in opioid receptors, L-arginine/NO/cGMP pathways and anti-inflammatory effects. Cuminaldehyde has potential application value in the research of neurodegenerative diseases, cancer, diabetes and neuropathic pain diseases .
    Cuminaldehyde (Standard)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: